Ascendis Pharma A/S (ASND) Stock Forecast & Price Target
Price as of Nov 16, 2026 (intraday, delayed) · Analyst estimates retrieved Nov 13, 2026 · Source: Financial Modeling Prep (analyst estimates) (methodology)
Revenue and earnings estimates published by analysts covering Ascendis Pharma A/S (ASND), and the range of their price targets. Everything on this page is a forecast made by other people — DeltaScreener does not produce estimates or targets of its own.
For Ascendis Pharma A/S, analysts forecast revenue rising from EUR 708.27M in 2025 to EUR 3.39B in 2030; the average estimate for 2030 earnings per share is EUR 20.51; with published estimates ranging from EUR 18.99 to EUR 23.32; 15 analysts contribute to these figures. These are forecasts published by analysts, not results.
Analyst price targets
A price target is one analyst's forecast of where a share might trade, usually over twelve months. Targets are frequently revised, they disagree with each other, and they are not a measure of what a company is worth.
Revenue forecast (EUR)
The spread between low and high is how far analysts disagree, which is usually a better guide than the average alone.
Earnings per share forecast (EUR)
Ascendis Pharma A/S (ASND) forecast — frequently asked questions
What is the analyst price target for Ascendis Pharma A/S?
Analysts covering Ascendis Pharma A/S (ASND) have a consensus price target of $306.33, 12.6% above the current price of $272.12. Published targets range from $268.00 to $344.00. A price target is a forecast, not a measure of value, and targets are revised often.
What are analysts forecasting for Ascendis Pharma A/S's earnings?
The average analyst estimate for Ascendis Pharma A/S (ASND) earnings per share in 2030 is 20.51, with individual estimates between 18.99 and 23.32.
How much revenue is Ascendis Pharma A/S expected to make?
Analysts forecast Ascendis Pharma A/S (ASND) revenue of EUR 3.39B in 2030, based on 11 published estimates.
How many analysts cover ASND?
15 analysts contribute estimates for Ascendis Pharma A/S (ASND). Thin coverage makes an average less reliable.
Analyst forecasts for other Biotechnology stocks
Popular Stocks
Related stock screens
Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.